In NAFLD, negative regulation in the activity of the transcription factor peroxisome proliferator-activated receptor-α (PPAR-α) that reduces fatty acid (FA) oxidation, with a concurrent positive control in the activity of the lipogenic transcription factor sterol regulatory element-binding protein-1c (SREBP-1c), is reported [24]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatotic liver disease.